Letter From The Editor

Things are in full swing at AACE this weekend and we will be bringing you the most important and usable information in next week’s newsletter.    One of the most talked-about insulin-delivery products is the V-Go insulin delivery device. Early results from the "SIMPLE" study followed patients who switched from …

Last week in our Homerun Slides we started to talk about quality measures in patient care. Whenever we get information about this concept it always revolves around the practitioner, and how good a job we do, but often patient care is dictated by the payor  and the benefits they allow. …

This week there is a new report out on the increased spending per year for diabetes care. This number is now well over 240 billion dollars, and when you add that to the 140 billion dollars we spend on hypertension we are now at almost 400 billion for the two …

There is a lot of clamor about the new way of providing healthcare, and how quality becomes important to maximize reimbursement potential. A part of this quality initiative involves Value Based Purchasing. To help you understand the concept of VBP as it is called, we are providing you with a …

If you have been a little behind on reading your emails you might not yet have seen the special edition that we sent out on the new SGLT2-Inhibitors now that the first in class drug has been approved for sale in the US. Since we first put this together I …

This week we continue our Clinical Text focus on macrovascular disease associated with diabetes. Dr. Beaser gets into a discussion as to which patients should be on aspirin therapy and how the use of a particular ACE-inhibitor can make a significant difference in MI risk reduction. The Homerun Slides continue …

This past week I was in the DC area talking to physicians about patient-centered Medical Homes and Accountable Care Organizations (ACO’s). Much of the conversation revolved around Medicare and Medicaid plans and patients. As we were talking about opportunities for the future the conversation turned toward working directly with companies …

This week we are pleased to bring you a special edition on the new SGLT2 Inhibitors. While many other publications have had information on this new class and the first of its kind approved drug, we decided to go into much more depth in our delivery of information. The SGLT2 …

Our newly diagnosed patients receive so much information from friends, family, and the internet that they become desensitized to having diabetes and what that means in real terms. This overload of information and long list of do’s and don’ts can be blamed for many patients just giving up before they …

About three quarters of our diabetes patients have dyslipidemia and elevated triglycerides, along with high insulin resistance and an increased risk of CAD. Our Clinical Text from Joslin looks at this problem and also answers the question of whether improving glucose control can impact lipid control. Many of the dyslipidemic …